Stocklytics Platform
Asset logo for symbol SUPN
Supernus Pharmaceuticals
SUPN63
$28.92arrow_drop_down0.05%-$0.01
Asset logo for symbol SUPN
SUPN63

$28.92

arrow_drop_down0.05%

Income Statement (SUPN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT-$4.24M$18.98M$9.43M-$15.42M$8.87M
EBITDA$16.50M$40.66M$31.29M$5.29M$28.84M
gross Profit$106.58M$123.01M$134.27M$114.47M$130.30M
NET Income$124.00K$1.17M-$15.97M-$831.00K$16.94M
total Revenue$143.64M$164.31M$153.88M$135.56M$153.76M

Balance Sheet (SUPN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt-$21.27M-$33.52M-$52.66M$17.49M$458.93M
stockholders Equity$929.16M$921.51M$912.19M$919.90M$912.15M
total Assets$1.30B$1.40B$1.28B$1.29B$1.79B
total Debt$42.12M$41.52M$42.32M$42.19M$517.37M
total Liabilities$374.92M$487.46M$372.96M$373.19M$879.65M

Cash Flow (SUPN)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$1.57M$1.09M-$230.00K-$478.91M$80.17M
free Cash Flow$38.15M$44.99M$35.72M-$19.03M$48.84M
investing Cash Flow---$60.29M$239.78M
operating Cash Flow$38.40M$44.95M$35.87M-$18.87M$49.12M

Supernus Pharmaceuticals (SUPN) Financials

SUPN's income statement provides a snapshot of the company's financial performance over a specific period. It includes information on revenues, expenses, profits, and losses. The income statement highlights key financial indicators such as gross profit, EBIT (earnings before interest and taxes), EBITDA (earnings before interest, taxes, depreciation, and amortization), and net income from stockholders. These figures help investors assess the company's profitability and financial health. For SUPN, the income statement shows a strong gross profit, indicating efficient cost management and pricing strategies. EBIT and EBITDA provide insights into the company's operating performance by measuring its ability to generate profits before considering non-operating expenses and depreciation. Net income from stockholders represents the profit remaining for equity shareholders after all expenses and taxes have been deducted. This figure reflects the company's earnings available for distribution to investors.

The total revenue reported by SUPN on its income statement represents the sum of all revenue streams generated by the company. It includes sales of its pharmaceutical products, royalties, licensing fees, and any other income related to its operations. Total revenue is a key measure of the company's overall sales performance and growth potential. It reveals the company's ability to attract customers and generate sales in the highly competitive pharmaceutical industry. SUPN's balance sheet provides a snapshot of its financial position at a specific point in time. It includes information on the company's assets, liabilities, and shareholders' equity. Total assets represent all the resources owned by the company, including cash, investments, property, and intellectual property rights. Total liabilities encompass the company's debts and obligations. Stockholders' equity reflects the net worth of the company and represents the residual interest of shareholders in its assets after deducting liabilities. It is an indication of the company's financial health and its ability to generate returns for shareholders.

SUPN's cash equivalents are highly liquid assets that can be readily converted into cash. These include short-term investments such as marketable securities and treasury bills. Cash equivalents are an important component of a company's liquidity and financial stability. Net debt is calculated by subtracting a company's cash and cash equivalents from its total debt. It represents the company's overall indebtedness and its ability to meet its financial obligations. A negative net debt indicates that the company has more cash and cash equivalents than its total debt, which is generally considered a positive sign. Stockholders' equity represents the residual interest in the company's assets after deducting liabilities. It is an important measure of a company's financial health and its ability to generate returns for shareholders. Total assets represent the company's total resources, including cash, investments, property, and intellectual property rights. Total debt is the sum of all the company's outstanding debts and obligations. It includes long-term and short-term debt, such as loans, bonds, and credit lines. Total liabilities encompass the company's debts and obligations to both internal and external stakeholders. These figures are important indicators of the company's financial strength and its ability to meet its obligations and generate returns for investors.

SUPN's cash flow statement shows how the company generates and uses cash over a specific period. It includes information on the company's operating cash flow, investing cash flow, and financing cash flow. Operating cash flow measures the cash generated or used by the company's core operations, such as revenue from sales and expenses related to production. Investing cash flow represents the cash used for investments in assets such as property, plant, and equipment or acquisitions of other companies. Financing cash flow reflects the cash flow resulting from changes in the company's capital structure, including proceeds from issuing debt or equity and the repayment of debt. Free cash flow represents the cash generated by the company after deducting capital expenditures and other investments necessary to maintain or expand its business. It is an important measure of the company's financial health and its ability to fund growth initiatives and return cash to shareholders. By analyzing SUPN's cash flow statement, investors can assess the company's ability to generate cash and its overall financial stability.

add Supernus Pharmaceuticals  to watchlist

Keep an eye on Supernus Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level